Latest news with #Halozyme
Yahoo
6 days ago
- Business
- Yahoo
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
Wells Fargo analyst Mohit Bansal notes that PTAB has instituted Merck's (MRK) patent grant review against Halozyme Therapeutics (HALO) MDASE patents. This patent is one of the patents Merck is fighting against Halozyme. The firm believes this likely reduces the probability of Halozyme prevailing in this case and weakens the bull argument. Wells has an Equal Weight on Halozyme with a price target of $65 on the shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on HALO: Disclaimer & DisclosureReport an Issue Merck granted review of Halozyme patent claims by PTAB Halozyme's Strategic Positioning and Market Potential Drive Buy Rating Halozyme announces EC approval of Bristol Myers' Opdivo developed with Enhanze Optimistic Buy Rating for Halozyme Amid Price Control Concerns Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
Yahoo
6 days ago
- Business
- Yahoo
Merck granted review of Halozyme patent claims by PTAB
The USPTO's Patent Trial and Appeal Board instituted Merck's (MRK) patent grant review against Halozyme's (HALO) MDASE patents after Merck filed a Petition requesting post-grant review of claims 1-21 of U.S. Patent No. 11,952,600, according to a post to the site of the USPTO. In consideration of 'the Petition, Preliminary Response, Reply, Sur-Reply, and the evidence of record, we determine that the information presented shows that it is more likely than not that Petitioner would prevail in establishing unpatentability of claims 1-4 and 8-21 of the '600 patent,' the board decision stated. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on HALO: Disclaimer & DisclosureReport an Issue Halozyme's Strategic Positioning and Market Potential Drive Buy Rating Halozyme announces EC approval of Bristol Myers' Opdivo developed with Enhanze Optimistic Buy Rating for Halozyme Amid Price Control Concerns Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley Hold Rating Issued Amid Uncertainty in Drug Pricing Regulations Impacting Halozyme Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday
We recently published a list of . In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against other Wednesday's best-performing stocks. The stock market rebounded on Wednesday, with all major indices ending in the green as investors cheered the Federal Reserve's decision to keep interest rates unchanged. On Wednesday afternoon, the Fed kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still 'wait and see' the impact of President Donald Trump's tariff policies. The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent. Beyond the major indices, 10 firms stood out with strong gains, thanks to a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Wednesday's 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. An image of a research technician wearing lab coat with a syringe full of biopharmaceuticals. Halozyme Therapeutics saw its share prices soar by 18.12 percent on Wednesday to end at $70.14 apiece as investor sentiment was buoyed by its impressive earnings performance in the first quarter of the year. During the period, Halozyme Therapeutics, Inc. (NASDAQ:HALO) netted $118 million, higher by 53.6 percent than the $76.8 million registered in the same period last year. Revenues increased by 35 percent to $264.86 million from $195.88 million year-on-year, thanks to higher royalty revenue and increased sales from rHuPH20, an enzyme that facilitates SC delivery of high-dose, high-volume therapeutics. Following the strong quarter, Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its revenue outlook guidance for full-year 2025, now targeting a range of $1.2 billion to $1.28 billion, as compared with the $1.15 billion to $1.225 billion previously. Of the total, royalty revenues are expected to reach between $750 million and $785 million, higher than the $725 million to $750 million as previously targeted. Overall, HALO ranks 4th on our list of Wednesday's best-performing stocks. While we acknowledge the potential of HALO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than HALO but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
05-05-2025
- Business
- Yahoo
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-359-3016tbui@ Samantha View original content to download multimedia: SOURCE Halozyme Therapeutics, Inc. Sign in to access your portfolio
Forbes
30-04-2025
- Business
- Forbes
InnovationRx: A Patent Fight Over The World's Top-Selling Drug
In this week's edition of InnovationRx, we look at a patent fight over the world's top-selling drug, breakthroughs from the American Association for Cancer Research, Verily's Parkinson's dataset, the relationship between microplastics and heart disease, and more. To get it in your inbox, subscribe here. Robert Davis, chief executive officer of Merck & Co. Merck's Keytruda is the world's top-selling drug, bringing in nearly $30 billion in sales last year. The drug, which is used to treat lung cancer, melanoma and certain other cancers, has historically been given by intravenous infusion, but Merck is gearing up to launch an injectable version that would be easier on patients. That formulation is currently pending FDA approval (the agency has a target of September 23 to decide) and, if approved, Merck has said it plans to launch on October 1. San Diego-based Halozyme is fighting that plan–and last week filed suit in U.S. District Court in New Jersey, alleging that the injectable version of Keytruda infringes on its patents. Halozyme, which is publicly traded with a market cap of $7.5 billion, partners with pharmaceutical companies to make injectable versions of important medicines, and said that it had expected Merck to sign a licensing deal in order to use its hyaluronidase technology. It's now seeking an injunction to block Merck's planned commercialization of the drug. Merck has said that the suit is 'meritless.' The court battle comes at a critical time for Keytruda, which is facing the approaching expiration of some key patents starting in 2028 that could potentially open the way for less costly versions known as biosimilars. Merck's efforts to change the blockbuster drug's delivery system could potentially both increase its sales and extend its patent runway. On Tuesday, Merck said that it would spend $1 billion on a new factory in Delaware that would include biologic drugs, the new injectable version of Keytruda among them. More than 21,000 people gathered over the past few days at the annual meeting of the American Association of Cancer Research in Chicago. Companies presented innovative research, suggesting hope for patients against some of the world's deadliest diseases. Here are a few highlights from the meeting: Diagnostic Help From AI: Artificial intelligence is proving to be helpful in better diagnosing cancer. In one new academic paper, an AI model was able to predict whether a cancer patient is at risk of developing wasting disease better than conventional methods. Other research found that an AI model was able to classify sarcomas (cancers that attack soft tissues) from images alone, a task that normally requires complex chemical analysis. And in a third study, AI was used to help diagnose nonmelanoma skin cancers. Promise For Boehringer Ingleheim's Lung Cancer Drug: Just under 5% of patients with non-small cell lung cancer have a mutation in a gene called HER2 that results in much more aggressive tumors that are harder to treat, because the mutations closely resemble other proteins in the body, which can cause toxic side effects. Pharmaceutical company Boehringer Ingelheim presented data from a clinical trial of its drug zongertinib, which binds tightly to HER2 proteins. The study found a durable response to the drug in patients with lower rates of adverse side effects than comparable treatments. Promising Immunotherapies: An off-the-shelf cell therapy developed by Sentio Biosciences caused complete remission in blood cancer patients with fewer side effects than a typical CAR-T treatment in a small phase 1 clinical trial. Plus, a study from the Dana-Farber Cancer Institute found that the use of immunotherapy both before and after surgery improved outcomes for patients with head and neck cancer. One Shot For HPV: A large-scale clinical study conducted by the National Cancer Institute suggests that Gardisil, a vaccine that protects against HPV, is just as effective at preventing cervical cancer after only one dose as the current schedule of two doses currently prescribed in the United States. Sudip Parikh, CEO of the American Association for the Advancement of Science, which publishes the Science family of journals, testified to the Senate Appropriations Committee about the state of biomedical research in the United States on Wednesday. In his testimony, Parikh criticized the execution of cuts to jobs and grants to scientific agencies by the Trump administration. 'Too many game-changing decisions are being made by individuals with little to no understanding of the complex ecosystem,' he testified. He also criticized proposed budget cuts to NIH, stating that they would lead to fewer treatments for cancer, dementia and other maladies and cost America its leadership in the field. 'Unfortunately, the implementation and execution of these efforts have caused both collateral and targeted damage to the biomedical research enterprise,' he stated in his prepared comments. 'And — if rumored proposed budgets for 2026 are realized – will hand leadership of biomedical research to China and, even more devastatingly, dismantle the engine of hope and prosperity for millions of Americans.' A new study by a team of economists at American University's Institute for Macroeconomic and Policy Analysis found that a 25% reduction in research funding would lower government revenues 4.3% in the long term, while a 75% cut would lower it 11.3%–more than since the Great Depression. Plus: The FDA approved Abeone Therapeutics' gene therapy Zevaskyn, which is used to treat a rare genetic condition that causes extremely fragile skin, leading to blistering and other wounds over the body. Verily, Alphabet's health and AI company, received a $14.7 million grant from the Michael J. Fox Foundation to build a large molecular dataset of Parkinson's patients. The dataset is designed to help researchers better understand the relationship between genetics, immunology and metabolism, which could accelerate new treatments for the debilitating neurological disease. As many as 1 million people in the U.S. have Parkinson's disease with nearly 90,000 new cases diagnosed annually. Diagnostics company Predicta Biosciences announced the commercial launch of its first test, GenoPredicta. The test uses whole genome sequencing of blood or bone marrow from patients to detect genetic variations that can diagnose and guide treatment for multiple myeloma (a blood cancer). The test is intended as a next generation of diagnostics, enabling more accurate diagnosis than the current standard, fluorescence in situ hybridization, without requiring the painful intrusion of a bone marrow biopsy. The company's test can also identify genetic mutations that indicate a patient won't respond to a particular medicine. 'There's really a lot of benefits both from the blood-based side and from the whole genome sequencing side, which gives us just a much more complete view of the alterations in that patient's cancer than the current standard does,' cofounder Irene Ghobrial, who's also a professor at the Dana Farber Cancer Institute, told Forbes. A new study published this week suggests that exposure to phthalates, a class of chemicals used to make plastic used in household items, may be linked to hundreds of thousands of deaths from heart disease each year. The study focused on a specific phthalate called DEHP, which can prompt inflammation in the heart's arteries, leading to disease. The study estimates exposure to DEHP caused more than 350,000 deaths from heart disease–about 13% of all heart disease deaths–in 2018 alone. Novo Nordisk will sell low-cost versions of its popular weight-loss drug Wegovy through telehealth companies Hims, Ro and LifeMd. The three companies had been selling compounded versions of the drug, which the FDA permitted when there was a shortage, but that shortage was declared ended last month. Compounding pharmacies have filed suit to keep being able to produce those versions. (Disclosure: Forbes Media owns a small stake in Ro.) Plus: IVF automation company Overture Life raised $21 million from Overwater Ventures, GV and Khosla Ventures bringing its total investment to $57 million at an undisclosed valuation. The Palo Alto, Calif.-based company uses software and robotics to bring down the costs of fertility procedures. As Trump pushes coal, a federal program to screen coal miners for deadly black lung disease has been shuttered. The shingles vaccine appears to lower dementia risk, according to several recent studies. Measles continues to spread in the United States, with over 900 cases nationwide, putting the country at a tipping point for the return of endemic measles for the first time since it was declared eradicated 25 years ago, new research warns. Damage from a gut bacteria may help explain why colon cancers have been rising in people under age 55. Chinese biotech Akeso won approval in China for its drug challenging Merck's Keytruda. Summit Therapeutics has a deal with Akeso for the drug's development in the U.S. Trump's cuts to science funding mean that mice, rats and even monkeys used in research face being euthanized. Health system operating margins dropped below 1% in March, according to a report from Strata.
